SEARCH
検索詳細
長谷 敬太郎 (ハセ ケイタロウ)
| 北海道大学病院 脳・神経・感覚器科 眼科 | 特任助教 |
研究者基本情報
■ URLresearchmap URLホームページURL■ ID 各種
研究者番号
- 70880376
研究キーワード研究分野
研究活動情報
■ 受賞■ 論文
- The Role of Plasminogen Activator Inhibitor-1 in Uveitis: Findings from Clinical and Experimental Studies.
Kayo Suzuki; Daiju Iwata; Kenichi Namba; Keitaro Hase; Miki Hiraoka; Miyuki Murata; Nobuyoshi Kitaichi; Shigeaki Ohno; Susumu Ishida
Current eye research, 51, 7, 788, 795, 2026年07月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Plasminogen activator inhibitor (PAI) -1 is a key regulator of endogenous fibrinolysis and is widely acknowledged as a its primary inhibitor. Beyond this function, PAI-1 also plays a role in macrophage migration during inflammatory conditions. This study aims to investigate the contribution of PAI-1 to the progression of uveitis. METHODS: We quantified PAI-1 protein levels in vitreous samples collected from uveitis patients utilizing a magnetic bead-based multiplex immunoassay. To clarify the changes in PAI-1 expression in uveitis, experimental autoimmune uveoretinitis (EAU) was induced in mice through immunization with bovine retinal antigens. The mRNA levels of PAI-1 in the retinochoroidal tissues of EAU mice and control mice, which were immunized without retinal antigen, were examined using quantitative real-time RT-PCR. The severity of EAU treated with the PAI-1 inhibitor; IMD4482, was clinically assessed over time. Furthermore, THP-1 macrophages were cultured with PAI-1 and each concentration of IMD4482 (0 μM, 0.1 μM, 1 μM, 10 μM and 100 μM) for 24 h. The number of migrated cells was quantified using a transwell assay. RESULTS: Vitreous PAI-1 protein levels were markedly eleveted in uveitis patients compared to controls (p < 0.01). In EAU mice, retinochoroidal PAI-1 mRNA expression was significantly higher than in control mice (n = 6, p = 0.03). Treatment with IMD4482 significantly reduced the clinical severity of EAU (n = 18-20, p < 0.01) and the migration of THP-1 macrophages was significantly inhibited by IMD4482 (100 μM; p < 0.01). CONCLUSION: Our findings indicate that the level of PAI-1 is locally high in the eye of uveitis patients as well as in experimental uveitis models. Suppression of EAU through PAI-1 inhibition highlights its potential as a therapeutic target for uveitis. - Clinical performance of the multiplex solid-phase "Direct Strip PCR" for infectious uveitis: a multicenter diagnostic accuracy study.
Satoko Nakano; Sunao Sugita; Hiroshi Takase; Yasuhiro Tomaru; Daisuke Todokoro; Yumi Hasegawa; Yasuhiro Ikeda; Go Mawatari; Chie Sotozono; Kenji Nagata; Kaoru Araki-Sasaki; Suguru Nakagawa; Yoshiaki Kiuchi; Kaori Mitoma; Nobuyo Yawata; Takehiro Hariya; Eiichi Uchio; Tomoko Tsukahara-Kawamura; Hidenori Inoue; Koji Toriyama; Sentaro Kusuhara; Wataru Matsumiya; Nobuyuki Ohguro; Hisashi Mashimo; Ken Fukuda; Waka Ishida; Mariko Egawa; Kei Nakai; Masakazu Morioka; Atsushi Hayashi; Tomoko Nakamura; Yoshihiko Usui; Hiroshi Goto; Ryohei Nejima; Kazunori Miyata; Kenichi Namba; Keitaro Hase; Annabelle A Okada; Hiroshi Keino; Nobuhisa Mizuki; Masaki Takeuchi; Dai Miyazaki; Kunihiro Kiyosaki; Reiko Kinouchi; Ryoji Yanai; Sho-Hei Uchi; Shigeko Yashiro; Rie Tanaka; Aika Tsutsui; Takashi Suzuki; Yukiko Umeki; Takaaki Yahiro; Akane Sonezaki; Takashi Matsumoto; Tetsuji Ohyama; Masae Kuranari; Naoto Uemura; Yuichi Hori; Atsunobu Takeda; Toshiaki Kubota; Toshikatsu Kaburaki; Koh-Hei Sonoda; Manabu Mochizuki
Japanese journal of ophthalmology, 70, 4, 966, 982, 2026年07月, [国内誌]
英語, 研究論文(学術雑誌), PURPOSE: To evaluate the clinical performance of "Direct Strip PCR," a multiplex solid-phase real-time polymerase chain reaction (PCR) kit, for diagnosing infectious uveitis. STUDY DESIGN: Multicenter, prospective, diagnostic accuracy study METHODS: We analyzed 475 ocular-fluid samples (336 aqueous humor and 139 vitreous fluid) from 29 sites in Japan. Direct Strip PCR, an IVD-grade multiplex real-time PCR kit targeting HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HTLV-1, Toxoplasma gondii, and Treponema pallidum requiring no DNA extraction and incorporating internal controls, was compared with quantitative PCR (qPCR) for concordance and DNA copy-number correlation. RESULTS: All 9 of the target pathogens were detected. Direct Strip PCR showed excellent agreement with qPCR, with percent positive agreement (PPA), percent negative agreement (PNA), and percent overall agreement (POA) in aqueous humor of 98.0%, 99.2%, and 98.5%, respectively, and in vitreous fluid of 95.7%, 97.1%, and 96.4%, respectively, indicating high concordance for positive and negative results. All the values exceeded predefined 90% thresholds agreed upon with the Pharmaceuticals and Medical Devices Agency, meeting the required performance criteria. Discordant results were infrequent (10/4275 targets) and involved low-copy samples near the detection limit. The DNA copy numbers correlated strongly between the methods (r = 0.948-0.996). No adverse events were reported. CONCLUSION: Direct Strip PCR demonstrated high concordance with qPCR, reliably detected major pathogens of infectious uveitis, and yielded quantitative results that correlated with the qPCR results, supporting disease monitoring. Its solid-phase, extraction-free, and per-run calibration-free format provides a practical basis for regulatory submissions and global dissemination of multiplex PCR. - Macrophage immunosenescence prolongs intraocular inflammation in aged mice via impaired induction of regulatory T cells.
Taku Yamamoto; Keitaro Hase; Joseph B Lin; Shinobu Yamaguchi; Norihiko Misawa; Jiayi Li; Kenta Kato; Ryo Terao; Brian S Sohn; Daniel Du; Mitsukuni Yoshida; Charles W Pfeifer; Tae Jun Lee; Jason Colasanti; Andrea Santeford; James T Walsh; Rajendra S Apte
bioRxiv : the preprint server for biology, 2026年01月20日, [国際誌]
英語, 研究論文(学術雑誌), Immune-mediated intraocular inflammation, called uveitis, is a leading cause of global blindness, with the highest burden of visual impairment falling on older individuals. Immunosenescence, the functional changes in immune cells with aging, impacts the age-associated immune response, but how immunosenescence and the molecular regulators of the age-associated immune response affect the clinical course of uveitis remains unclear. In the murine model of experimental autoimmune uveitis (EAU), aged mice demonstrated a delayed onset and peak of intraocular inflammation compared to young mice. In contrast to the canonical monophasic inflammation that rapidly resolves in young mice, aged mice developed persistent, chronic inflammation. Transcriptomic and flow-cytometric analyses of immune cells and the receptor-ligand interactome revealed a dominant macrophage-CD4+ T cell signature. This signaling pathway was functionally altered on both ends: macrophages from aged mice had an impaired capacity to generate peripherally induced regulatory T cells (pTreg) through an IL-6 regulated pathway, while CD4+ T cells co-cultured with aged macrophages demonstrated increased proliferation. Our study establishes aging as a key regulator of the effector immune response in uveitis. Regulatory T cells, specifically pTreg, are essential for resolving inflammation in uveitis and an impaired ability to induce pTreg led to a sustained, chronic inflammatory uveitis phenotype in old mice, thereby linking immunosenescence to persistent neuroinflammation. These findings highlight potential therapeutic avenues for vision-threatening uveitis, especially in older patients. - A Case of Refractory Panuveitis with Coexisting Spondyloarthritis Successfully Treated with Tofacitinib.
Ayano Wakabayashi; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Keitaro Hase; Kayo Suzuki; Yo Ogino; Miki Hiraoka; Nobuyoshi Kitaichi; Shuhei Takeyama; Tatsuya Atsumi; Susumu Ishida
Case reports in ophthalmology, 17, 1, 281, 288, 2026年, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Non-infectious uveitis is commonly treated with corticosteroids, immunosuppressants, and, recently, TNF inhibitors. However, some patients do not achieve adequate control of uveitis with these drugs. This report presents a case of panuveitis with coexisting spondyloarthritis (SpA) in which both TNF and interleukin-17 (IL-17) inhibitors failed to control uveitis, but tofacitinib, a Janus kinase (JAK) inhibitor, was effective in treating uveitis. CASE PRESENTATION: A 54-year-old woman visited our hospital with a complaint of blurred vision in her left eye. A small retinal exudate in the inferonasal region in the right eye and 2+ vitreous haze in the left eye were seen. Systemic examinations were performed, but no abnormal findings were detected. The patient subsequently had frequent ocular inflammatory recurrences; thus, Behçet's disease was suspected, although no characteristic extraocular symptoms were noted. In addition to colchicine, adalimumab was administered, but the patient still showed frequent ocular inflammatory attacks. The patient subsequently developed arthritis and was diagnosed with axial SpA. Despite treatment with infliximab (TNF alpha inhibitor) or secukinumab (IL-17 inhibitor), ocular inflammatory attacks persisted, resulting in decreased visual acuity attributed to complicated cataracts. After cataract surgery, oral tofacitinib, a JAK inhibitor, was initiated. Afterward, ocular attacks did not occur for more than 3 years, and her visual acuity remained at 1.0 in both eyes. CONCLUSION: We examined a case of panuveitis with coexisting SpA refractory to TNF inhibitor and IL-17 inhibitor, in which JAK inhibitor was successfully effective. JAK inhibitors may be useful for some patients with refractory uveitis. - Acute retinal necrosis during the systemic use of Janus kinase inhibitor.
Daisuke Watanabe; Kenichi Namba; Keitaro Hase; Kayo Suzuki; Yo Ogino; Michiyuki Saito; Daiju Iwata; Kazuomi Mizuuchi; Miki Hiraoka; Mao Narita; Nobuyoshi Kitaichi; Norihiko Kitaya; Susumu Ishida
International journal of retina and vitreous, 11, 1, 135, 135, 2025年12月04日, [国際誌]
英語 - 【超高齢化社会におけるぶどう膜炎】わかりやすい臨床講座 超高齢社会とぶどう膜炎続発緑内障
長谷 敬太郎
日本の眼科, 96, 9, 1090, 1095, (公社)日本眼科医会, 2025年09月
日本語 - 急性後部多発性斑状色素上皮症(APMPPE)に脱毛を合併した1例
成瀬 早紀; 高島 翔太; 氏家 英之; 長谷 敬太郎
日本皮膚科学会雑誌, 135, 8, 1929, 1929, (公社)日本皮膚科学会, 2025年07月
日本語 - Analysis of retinal immunosenescence in uveitis using single-cell sequencing
Taku Yamamoto; Keitaro Hase; Joseph B. Lin; James Walsh; Shinobu Smithson; Charles W. Pfeifer; Tae Jun Lee; Jason Colasanti; Andrea Santeford; Mitsukuni Yoshida; Rajendra S. Apte
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 66, 8, 2025年06月
英語 - Protocol for Japan-acute retinal necrosis (J-ARN) registry: A combined prospective and retrospective cohort study.
Yoshihiko Usui; Reiko Kinouchi; Satoko Nakano; Chiharu Iwahashi; Keitaro Hase; Kenji Nagata; Masahiro Sugimoto; Eiichi Hasegawa; Kinya Tsubota; Sentaro Kusuhara; Masato Akiyama; Kenji Kashiwagi; Atsunobu Takeda; Toshikatsu Kaburaki; Hiroshi Goto; Koh-Hei Sonoda
PloS one, 20, 5, e0323822, 2025年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Acute retinal necrosis (ARN) is a rare but vision-threatening viral retinitis that can lead to severe visual impairment or blindness if not diagnosed and treated promptly. However, due to its rarity, there are limited large-scale data on the clinical characteristics, treatment approaches, and outcomes of ARN in Japan. A nationwide registry is needed to systematically collect data on ARN cases across Japan to improve understanding of this condition and optimize patient care. We have designed a national registry that collects data of patient characteristics, diagnosis, treatment, and visual outcome to generate evidence for the management of ARN. METHODS AND DESIGN: This research is a combined retrospective and prospective, multicenter cohort study of ARN in Japan from 1 April 2014-31 March 2029 (UMIN000056246). The registry has received Japan-wide approval from a national human research ethics committee. The following data will be collected: patient demographics, visual function at the initial visit and 6, 12, 24, and 36 months later, image data, diagnostic methods, virus analysis, indications and timing of vitrectomy, and complications. Customized software and platforms have been designed to permit data collection for a single baseline and multiple follow-up forms. DISCUSSION: By analyzing the accumulated patient information, the results of this study will generate real-world evidence that will contribute to solve various important clinical issues in ARN. The results will be presented after data collection and analysis are completed. - Involvement of epidermal growth factor receptor pathway in experimental autoimmune uveoretinitis
Koichi Yokoi; Kenichi Namba; Miyuki Murata; Kayo Suzuki; Keitaro Hase; Daiju Iwata; Nobuyoshi Kitaichi; Miki Hiraoka; Susumu Ishida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 65, 7, 2024年06月
英語 - LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD+ depletion.
Ryo Terao; Tae Jun Lee; Jason Colasanti; Charles W Pfeifer; Joseph B Lin; Andrea Santeford; Keitaro Hase; Shinobu Yamaguchi; Daniel Du; Brian S Sohn; Yo Sasaki; Mitsukuni Yoshida; Rajendra S Apte
Cell reports, 43, 5, 114102, 114102, 2024年05月28日, [国際誌]
英語, 研究論文(学術雑誌), Although dysregulated cholesterol metabolism predisposes aging tissues to inflammation and a plethora of diseases, the underlying molecular mechanism remains poorly defined. Here, we show that metabolic and genotoxic stresses, convergently acting through liver X nuclear receptor, upregulate CD38 to promote lysosomal cholesterol efflux, leading to nicotinamide adenine dinucleotide (NAD+) depletion in macrophages. Cholesterol-mediated NAD+ depletion induces macrophage senescence, promoting key features of age-related macular degeneration (AMD), including subretinal lipid deposition and neurodegeneration. NAD+ augmentation reverses cellular senescence and macrophage dysfunction, preventing the development of AMD phenotype. Genetic and pharmacological senolysis protect against the development of AMD and neurodegeneration. Subretinal administration of healthy macrophages promotes the clearance of senescent macrophages, reversing the AMD disease burden. Thus, NAD+ deficit induced by excess intracellular cholesterol is the converging mechanism of macrophage senescence and a causal process underlying age-related neurodegeneration. - Dysregulated CD200-CD200R signaling in early diabetes modulates microglia-mediated retinopathy.
Charles W Pfeifer; James T Walsh; Andrea Santeford; Joseph B Lin; Wandy L Beatty; Ryo Terao; Yizhou A Liu; Keitaro Hase; Philip A Ruzycki; Rajendra S Apte
Proceedings of the National Academy of Sciences of the United States of America, 120, 45, e2308214120, 2023年11月07日, [国際誌]
英語, 研究論文(学術雑誌), Diabetic retinopathy (DR) is a neurovascular complication of diabetes. Recent investigations have suggested that early degeneration of the neuroretina may occur prior to the appearance of microvascular changes; however, the mechanisms underlying this neurodegeneration have been elusive. Microglia are the predominant resident immune cell in the retina and adopt dynamic roles in disease. Here, we show that ablation of retinal microglia ameliorates visual dysfunction and neurodegeneration in a type I diabetes mouse model. We also provide evidence of enhanced microglial contact and engulfment of amacrine cells, ultrastructural modifications, and transcriptome changes that drive inflammation and phagocytosis. We show that CD200-CD200R signaling between amacrine cells and microglia is dysregulated during early DR and that targeting CD200R can attenuate high glucose-induced inflammation and phagocytosis in cultured microglia. Last, we demonstrate that targeting CD200R in vivo can prevent visual dysfunction, microglia activation, and retinal inflammation in the diabetic mouse. These studies provide a molecular framework for the pivotal role that microglia play in early DR pathogenesis and identify a potential immunotherapeutic target for treating DR in patients. - The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt-Koyanagi-Harada Disease.
Mayuko Shinagawa; Kenichi Namba; Kazuomi Mizuuchi; Daiju Iwata; Keitaro Hase; Kayo Suzuki; Kiriko Hirooka; Nobuyoshi Kitaichi; Miki Hiraoka; Susumu Ishida
Ocular immunology and inflammation, 31, 3, 501, 505, 2023年04月, [国際誌]
英語, 研究論文(学術雑誌) - 日本におけるフックス虹彩毛様体炎症候群の低い有病率の原因についての検討
米田 優; 臼井 嘉彦; 田中 理恵; 長谷 敬太郎; 南場 研一; 鴨居 功樹; 高瀬 博; 竹内 正樹; 松宮 亘; 楠原 仙太郎; 武田 篤信; 八幡 信代; 柳井 亮二; 日山 知奈; 原田 陽介; 橋田 徳康; 丸山 和一; 中井 慶; 田口 諒; 蕪城 俊克; 水木 信久; 後藤 浩; 藤野 雄次郎; 竹内 大
日本眼科学会雑誌, 127, 臨増, 270, 270, (公財)日本眼科学会, 2023年03月
日本語 - Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.
Masaru Takeuchi; Yoshihiko Usui; Kenichi Namba; Hiroshi Keino; Masaki Takeuchi; Hiroshi Takase; Koju Kamoi; Keitaro Hase; Takako Ito; Kei Nakai; Kazuichi Maruyama; Eri Kobayashi; Hisashi Mashimo; Tomohito Sato; Nobuyuki Ohguro; Junko Hori; Annabelle A Okada; Koh-Hei Sonoda; Nobuhisa Mizuki; Hiroshi Goto
Frontiers in medicine, 10, 1095423, 1095423, 2023年, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: To evaluate 10-year outcome of infliximab (IFX) treatment for uveitis in Behçet disease (BD) patients using a standardized follow-up protocol. DESIGN: Retrospective longitudinal cohort study. PARTICIPANTS: 140 BD uveitis patients treated with IFX enrolled in our previous study. METHODS: Medical records were reviewed for demographic information, duration of IFX treatment, number of ocular attacks before IFX initiation, best corrected visual acuity (VA) at baseline and 1, 2, 3, 4, 5, and 10 years after IFX initiation, uveitis recurrence after IFX initiation and main anatomical site, concomitant therapies, and adverse events (AEs). MAIN OUTCOME MEASURES: 10-year IFX continuation rate and change in LogMAR VA. RESULTS: Of 140 BD patients, 106 (75.7%) continued IFX treatment for 10 years. LogMAR VA improved gradually after initiation of IFX, and the improvement reached statistical significance from 2 years of treatment. Thereafter, significant improvement compared with baseline was maintained until 10 years, despite a slight deterioration of logMAR VA from 5 years. However, eyes with worse baseline decimal VA < 0.1 showed no significant improvement from baseline to 10 years. Uveitis recurred after IFX initiation in 50 patients (recurrence group) and did not recur in 56 (non-recurrence group). Ocular attacks/year before IFX initiation was significantly higher in the recurrence group (2.82 ± 3.81) than in the non-recurrence group (1.84 ± 1.78). In the recurrence group, uveitis recurred within 1 year in 58% and within 2 years in 74%. Seventeen patients (34%) had recurrent anterior uveitis, 17 (34%) had posterior uveitis, and 16 (32%) had panuveitis, with no significant difference in VA outcome. In addition, logMAR VA at 10 years did not differ between the recurrence and non-recurrence groups. AEs occurred among 43 patients (30.7%), and 24 (17.1%) resulted in IFX discontinuation before 10 years. CONCLUSIONS: Among BD patients with uveitis who initiated IFX, approximately 75% continued treatment for 10 years, and their VA improved significantly and was maintained for 10 years. Uveitis recurred in one-half of the patients, but visual acuity did not differ significantly from the patients without recurrence. - Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis.
Kayo Suzuki; Daiju Iwata; Kenichi Namba; Keitaro Hase; Miki Hiraoka; Miyuki Murata; Nobuyoshi Kitaichi; Richard Foxton; Susumu Ishida
PloS one, 18, 11, e0294745, 2023年, [国際誌]
英語, 研究論文(学術雑誌) - Fundus autofluorescence imaging in acute posterior multifocal placoid pigment epitheliopathy.
Koichi Yokoi; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Keitaro Hase; Kayo Suzuki; Ryo Ando; Kiriko Hirooka; Nobuko Sekine; Nobuyoshi Kitaichi; Miki Hiraoka; Susumu Ishida
American journal of ophthalmology case reports, 28, 101732, 101732, 2022年12月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) is a disease characterized by multiple yellowish-white placoid lesions. Although most lesions resolve spontaneously, some turn into scars and lead to permanent visual dysfunction. In this report, we found suggestive findings in fundus autofluorescence (FAF) that may be useful for distinguishing severe lesions requiring treatment in APMPPE. OBSERVATION: Case 1: A 29-year-old woman was referred to our hospital with multiple yellowish-white placoid lesions on the fundi of both eyes (OU). FAF showed hyperautofluorescence in some of these placoid lesions. Based on the findings of fluorescein angiography, a diagnosis of APMPPE was established, and oral prednisolone (PSL) was initiated, given that some lesions were located in the macula. One week later, exacerbation occurred with the newly developed hyperautofluorescent lesions. Some lesions in the right eye (OD) that were hyperautofluorescent at the first visit became hypoautofluorescent. Afterward, although all hypoautofluorescent lesions persisted, most of the hyperautofluorescent lesions disappeared, so oral PSL could be stopped. Two months later, however, the recurrence occurred along with multiple new placoid lesions. Some lesions located at the macula were hyperautofluorescent on FAF OU, indicating the possibility of becoming scar lesions with hypoautofluorescence. Accordingly, oral PSL was given again. CASE 2: A 47-year-old woman noticed decreased vision OD, and she was referred to us. Multiple yellowish-white placoid lesions were seen in the fundi OU. FAF showed hyperautofluorescence both with and without corresponding hypoautofluorescence in the placoid lesions OU. A diagnosis of APMPPE was established, and oral PSL was initiated. Four months later, some lesions that were hyperautofluorescent at the first visit had turned isoautofluorescent, and some lesions OU became hypoautofluorescent. However, all hypoautofluorescent lesions remained hypoautofluorescent OU. Only some hyperautofluorescent lesions recovered to isoautofluorescence without scars. CONCLUSIONS AND IMPORTANCE: In APMPPE, lesions showing hyperautofluorescence on FAF may change into hypoautofluorescence indicating scar formation. Therefore, the presence of hyperautofluorescent lesions in the macula may be a good indicator of the need for intensive corticosteroid treatments to avoid leaving hypoautofluorescent scars that are related to irreversible visual dysfunction. - Clinical significance of serum and vitreous soluble interleukin-2 receptor in patients with intraocular lymphoma.
Kayo Suzuki; Kenichi Namba; Satoru Kase; Yo Ogino; Keitaro Hase; Daiju Iwata; Kazuomi Mizuuchi; Miki Hiraoka; Nobuyoshi Kitaichi; Susumu Ishida
BMC ophthalmology, 22, 1, 428, 428, 2022年11月10日, [国際誌]
英語, 研究論文(学術雑誌) - Clinical features of ocular sarcoidosis: severe, refractory, and prolonged inflammation.
Kayo Suzuki; Mami Ishihara; Kenichi Namba; Shigeaki Ohno; Hiroshi Goto; Hiroshi Takase; Shigeru Kawano; Etsuko Shibuya; Keitaro Hase; Daiju Iwata; Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Nobuhisa Mizuki; Susumu Ishida
Japanese journal of ophthalmology, 66, 5, 447, 454, 2022年09月, [国内誌]
英語, 研究論文(学術雑誌) - Placental growth factor stabilizes VEGF receptor-2 protein in retinal pigment epithelial cells by downregulating glycogen synthase kinase 3 activity.
Miyuki Murata; Kousuke Noda; Satoru Kase; Keitaro Hase; Di Wu; Ryo Ando; Susumu Ishida
The Journal of biological chemistry, 298, 9, 102378, 102378, 2022年09月, [国際誌]
英語, 研究論文(学術雑誌) - Diagnostic Accuracy of Cell Block Preparations and Clinical Features Affecting It in Vitreoretinal Lymphoma.
Satoru Kase; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Kayo Suzuki; Takako Ito; Keitaro Hase; Nobuyoshi Kitaichi; Susumu Ishida
Journal of clinical medicine, 11, 5, 2022年03月03日, [国際誌]
英語, 研究論文(学術雑誌) - A case of Epstein-Barr virus acute retinal necrosis successfully treated with foscarnet.
Kayo Suzuki; Kenichi Namba; Keitaro Hase; Kazuomi Mizuuchi; Daiju Iwata; Takako Ito; Nobuyoshi Kitaichi; Hiroshi Takase; Susumu Ishida
American journal of ophthalmology case reports, 25, 101363, 101363, 2022年03月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis and several other human disorders. Ocular EBV infections that have been reported include uveitis, retinal vasculitis, and acute retinal necrosis (ARN). ARN is usually caused by herpes simplex virus (HSV) or varicella-zoster virus (VZV). ARN that is caused by EBV (EBV-ARN) is rarely seen, and only a few cases have been reported. The visual prognosis for EBV-ARN is poor, and no treatment strategy has been established. We report on a patient who was treated successfully for EBV-ARN. OBSERVATION: An 80-year-old female who had been treated with prednisolone at 5 mg/day and methotrexate at 2 mg/week for rheumatoid arthritis visited our hospital because of blurred vision in her left eye. Her left visual acuity was 20/50, and extensive white-yellowish retinal lesions at the temporal periphery with retinal hemorrhages were seen through vitreous haze. The DNA sequence of EBV, but not of HSV, VZV, or cytomegalovirus, was detected by a polymerase chain reaction (PCR) assay in the aqueous humor (4.2 × 106 copies/ml), with EBV also being positive in serum (3.5 × 102 copies/ml). The patient received 2 mg of intravitreal ganciclovir injections twice with a 3-day interval and intravenous infusion of acyclovir at 750 mg/day for 7 days; however, the retinal white lesions expanded rapidly, then dose of prednisolone was increased (40 mg/day) and vitrectomy was performed 10 days after the initial visit. After the surgery, the retinal lesion continued to enlarge. Vitreous samples showed high copies of EBV (1.2 × 108 copies/ml). Following treatment with intravenous foscarnet (4800 mg/day), which replaced the acyclovir application, the retinal white lesions gradually diminished, leaving retinal scars. To date, the patient has developed no retinal detachment and shows visual acuity over 6/60 in the left eye along with silicone oil. CONCLUSIONS: We experienced a case of EBV-ARN that was refractory to systemic acyclovir and topical ganciclovir but responded effectively to systemic foscarnet after vitrectomy. Although the clinical management remains challenging in this disease, foscarnet is considered to be one of the candidate drugs for EBV infections. - 日本におけるフックス虹彩毛様体炎症候群の低い有病率の原因についての検討
米田優; 臼井嘉彦; 田中理恵; 長谷敬太郎; 南場研一; 鴨居功樹; 高瀬博; 竹内正樹; 松宮亘; 楠原仙太郎; 武田篤信; 八幡信代; 柳井亮二; 日山知奈; 原田陽介; 橋田徳康; 丸山和一; 中井慶; 田口諒; 蕪城俊克; 水木信久; 後藤浩; 藤野雄次郎; 竹内大
日本眼科学会雑誌, 9, 999804, 999804, 2022年, [国際誌]
英語, 研究論文(学術雑誌) - Macrophage-like iPS-derived Suppressor Cells Reduce Th1-mediated Immune Response to a Retinal Antigen.
Keitaro Hase; Kenichi Namba; Haruka Wada; Hyuma Tsuji; Aoi Maeda; Tomoki Murata; Ryo Otsuka; Daiju Iwata; Atsuhiro Kanda; Kousuke Noda; Nobuyoshi Kitaichi; Ken-Ichiro Seino; Susumu Ishida
Current eye research, 46, 12, 1908, 1916, 2021年12月, [国際誌]
英語, 研究論文(学術雑誌) - 再発がみられた単純ヘルペスウイルス2型による急性網膜壊死の1例—A case of acute retinal necrosis recurrence caused by herpes simplex virus type 2
清野 修平; 南場 研一; 水内 一臣; 岩田 大樹; 鈴木 佳代; 品川 真有子; 長谷 敬太郎; 石田 晋
臨床眼科, 75, 12, 1527, 1532, 東京 : 医学書院, 2021年11月
日本語 - 網膜色素上皮細胞における胎盤成長因子による血管内皮増殖因子受容体-2の安定化機序
村田 美幸; 野田 航介; 長谷 敬太郎; Di Wu; 神田 敦宏; 石田 晋
日本糖尿病眼学会誌, 25, 126, 126, 日本糖尿病眼学会, 2021年08月
日本語 - Expression of Vascular Endothelial Growth Factor-C in the Trabecular Meshwork of Patients with Neovascular Glaucoma and Primary Open-Angle Glaucoma.
Keitaro Hase; Satoru Kase; Atsuhiro Kanda; Yasuhiro Shinmei; Kousuke Noda; Susumu Ishida
Journal of clinical medicine, 10, 13, 2021年07月02日, [国際誌]
英語, 研究論文(学術雑誌) - Development of cytomegalovirus retinitis after negative conversion of cytomegalovirus antigenemia due to systemic antiviral therapy.
Kayo Suzuki; Kenichi Namba; Kazuomi Mizuuchi; Daiju Iwata; Takako Ito; Keitaro Hase; Nobuyoshi Kitaichi; Susumu Ishida
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 259, 4, 971, 978, 2021年04月, [国際誌]
英語, 研究論文(学術雑誌) - Correction to: Development of cytomegalovirus retinitis after negative conversion of cytomegalovirus antigenemia due to systemic antiviral therapy.
Kayo Suzuki; Kenichi Namba; Kazuomi Mizuuchi; Daiju Iwata; Takako Ito; Keitaro Hase; Nobuyoshi Kitaichi; Susumu Ishida
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 259, 4, 1083, 1083, 2021年04月, [国際誌]
英語 - Validation of systemic parameters for the diagnosis of ocular sarcoidosis.
Kayo Suzuki; Kenichi Namba; Kazuomi Mizuuchi; Daiju Iwata; Takako Ito; Keitaro Hase; Nobuyoshi Kitaichi; Susumu Ishida
Japanese journal of ophthalmology, 65, 2, 191, 198, 2021年03月, [国内誌]
英語, 研究論文(学術雑誌) - Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.
Satoru Kase; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Takako Ito; Keitaro Hase; Kayo Suzuki; Masahiro Onozawa; Nobuyoshi Kitaichi; Susumu Ishida
Cancer diagnosis & prognosis, 1, 2, 69, 75, 2021年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND/AIM: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL). PATIENTS AND METHODS: Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement. RESULTS: Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation. CONCLUSION: Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period. - Receptor-Associated Prorenin System in the Trabecular Meshwork of Patients with Primary Open-Angle Glaucoma and Neovascular Glaucoma.
Erdal Tan Ishizuka; Atsuhiro Kanda; Yasuhiro Shinmei; Takeshi Ohguchi; Yoshiaki Tagawa; Keitaro Hase; Taku Yamamoto; Kousuke Noda; Shinki Chin; Susumu Ishida
Journal of clinical medicine, 9, 8, 2020年07月22日, [国際誌]
英語, 研究論文(学術雑誌) - Attenuation of experimental autoimmune uveoretinitis in mice by IKKβ inhibitor IMD-0354.
Ye Liu; Nobuyoshi Kitaichi; Di Wu; Keitaro Hase; Masashi Satoh; Daiju Iwata; Kenichi Namba; Atsuhiro Kanda; Kousuke Noda; Akiko Itai; Kazuya Iwabuchi; Susumu Ishida
Biochemical and biophysical research communications, 525, 3, 589, 594, 2020年05月07日, [国際誌]
英語, 研究論文(学術雑誌), Uveitis is a sight-threatening intraocular inflammatory disease that accounts for almost 10% of blindness worldwide. NF-κB signaling plays pivotal roles in inflammatory diseases. We have reported that IMD-0354, which inhibits NF-κB signaling via selective blockade of IKK-β, suppresses inflammation in several ocular disease models. Here, we examined the therapeutic effect of IMD-0354 in an experimental autoimmune uveoretinitis (EAU) model, a well-established animal model for endogenous uveitis in humans. Systemic administration of IMD-0354 significantly suppressed the clinical and histological severity, inflammatory edema, and the translocation of NF-κB p65 into the nucleus of retinas in EAU mice. Furthermore, IMD-0354 treatment significantly inhibited the levels of several Th1/Th17-mediated pro-inflammatory cytokines in vitro. Our current data demonstrate that inhibition of IKKβ with IMD-0354 ameliorates inflammatory responses in the mouse EAU model, suggesting that IMD-0354 may be a promising therapeutic agent for human endogenous uveitis. - Induced pluripotent stem cells-derived suppressor cells ameliorate experimental autoimmune uveoretinitis in mice
Keitaro Hase; Kenichi Namba; Nobuyoshi Kitaichi; Daiju Iwata; Hyuma Tsuji; Haruka Wada; Ken-ichiro Seino; Susumu Ishida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 60, 9, 2019年07月
英語 - A specific IKKβ inhibitor suppresses experimental autoimmune uveoretinitis in mice
Ye Liu; Nobuyoshi Kitaichi; Di Wu; Keitaro Hase; Daiju Iwata; Kenichi Namba; Atsuhiro Kanda; Kousuke Noda; Susumu Ishida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 60, 9, 2019年07月
英語 - Increased plasma galectin-1 correlates with advanced glycation end products and interleukin-1β in patients with proliferative diabetic retinopathy.
Keitaro Hase; Atsuhiro Kanda; Kousuke Noda; Susumu Ishida
International journal of ophthalmology, 12, 4, 692, 694, 2019年, [国際誌]
英語, 研究論文(学術雑誌) - Increased plasma galectin-1 is correlated with advanced glycation end products and interleukin-1β in patients with proliferative diabetic retinopathy
Keitaro Hase; Atsuhiro Kanda; Kousuke Noda; Susumu Ishida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 59, 9, 2018年07月
英語 - A comprehensive analysis of serum levels of prorenin/renin and inflammation-associated molecules in proliferative diabetic retinopathy
Keitaro Hase; Atsuhiro Kanda; Kousuke Noda; Susumu Ishida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 58, 8, 2017年06月
英語 - Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy.
Keitaro Hase; Atsuhiro Kanda; Ikuyo Hirose; Kousuke Noda; Susumu Ishida
PloS one, 12, 12, e0189696, 2017年, [国際誌]
英語, 研究論文(学術雑誌) - A case of tuberculous endophthalmitis successfully treated with vitrectomy followed by antituberculous agents.
Keitaro Hase; Kenichi Namba; Wataru Saito; Shigeaki Ohno; Susumu Ishida
Journal of ophthalmic inflammation and infection, 5, 14, 14, 2015年, [国際誌]
英語, 研究論文(学術雑誌) - Ectopic cilia: a histopathological study.
Keitaro Hase; Satoru Kase; Mika Noda; Tsutomu Ohashi; Satoru Shinkuma; Susumu Ishida
Case reports in dermatology, 4, 1, 37, 40, 2012年01月, [国際誌]
英語, 研究論文(学術雑誌)
- Vogt-小柳-原田病(再発・遷延型)—A Protracted Case of Vogt-Koyanagi-Harada Disease—特集 マルチモーダルイメージングとぶどう膜炎
長谷 敬太郎; 南場 研一, あたらしい眼科 / メディカル葵出版 [編], 42, 4, 399, 404, 2025年04月
東京 : メディカル葵出版, 日本語 - 眼トキソプラズマ症—Ocular Toxoplasmosis—特集 後眼部感染症アップデート
長谷 敬太郎, あたらしい眼科 / メディカル葵出版 [編], 41, 5, 509, 515, 2024年05月
東京 : メディカル葵出版, 日本語 - 緑内障眼に対する全層角膜移植術,角膜内皮移植術の術後経過の検討
櫻井淳; 石田晋; 木嶋理紀; 田川義晃; 大口剛司; 董震宇; 長谷敬太郎; 菊地香澄; 西村萌美; 金谷莉奈, 日本角膜学会総会・日本角膜移植学会プログラム・抄録集, 48th-40th, 2024年 - 実験的自己免疫性ぶどう膜網膜炎における上皮成長因子受容体経路の検討
横井康一; 南場研一; 村田美幸; 岩田大樹; 岩田大樹; 長谷敬太郎; 北市伸義; 平岡美紀; 北市伸義; 平岡美紀; 鈴木佳代; 石田晋, 日本眼科学会雑誌, 128, 臨増, 201, 201, 2024年
(公財)日本眼科学会, 日本語 - iPS細胞由来免疫抑制性細胞によるぶどう膜炎の軽症化
長谷敬太郎, 日本眼炎症学会誌, 26, 2024年 - 汎ぶどう膜炎に伴う網膜血管増殖性腫瘍が10年後に別部位に再発した1例
茶木駿; 南場研一; 岩田大樹; 水内一臣; 長谷敬太郎; 鈴木佳代; 荻野陽; 石田晋, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 60th-57th-7th, 2024年 - 白血病脈絡膜症のマルチモダルイメージング
廣岡季里子; 南場研一; 荻野陽; 鈴木佳代; 長谷敬太郎; 橋本大吾; 石田晋, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 60th-57th-7th, 2024年 - 本態性眼瞼痙攣患者における臨床的特徴の検討
金谷莉奈; 田川義晃; 新明康弘; 新明康弘; 藤田幸大; 荻野陽; 新海晃弘; 菊地香澄; 長谷敬太郎; 中村佳代子; 石田晋, 神経眼科, 40, 増補1, 56, 56, 2023年
日本神経眼科学会, 日本語 - 眼瞼痙攣患者の光遮断下,点眼麻酔投与下における最大開瞼時間の検討
藤田幸大; 田川義晃; 新明康弘; 新明康弘; 金谷莉奈; 荻野陽; 新海晃弘; 菊地香澄; 長谷敬太郎; 中村佳代子; 石田晋, 神経眼科, 40, 増補1, 77, 77, 2023年
日本神経眼科学会, 日本語 - 北海道大学病院眼科におけるDSAEK後の眼圧上昇の検討
藤田幸大; 田川義晃; 木嶋理紀; 渡邉竜也; 金谷莉奈; 西村萌美; 菊地香澄; 長谷敬太郎; DONG Zhenyu; 大口剛司; 石田晋, 日本緑内障学会抄録集, 34th, 208, 208, 2023年
日本緑内障学会, 日本語 - iPS細胞由来免疫抑制性細胞によるぶどう膜炎の軽症化
長谷敬太郎, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 59th-56th-65th-11th, 2023年 - Roles of adipose tissue metabolism on synthesis of photoreceptors outer segments and retinal senescence
Ryo Terao; Mitsukuni Yoshida; Tim Lee; Jason Colasanti; Chas W. Pfeifer; Joseph Lin; Andrea Santeford; Keitaro Hase; Kim Jongshin; Rajendra S. Apte, INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 63, 7, 2022年06月
英語, 研究発表ペーパー・要旨(国際会議) - Angiopoietin 2とvascular endothelial growth factorの眼炎症への関与
鈴木佳代; 岩田大樹; 南場研一; 長谷敬太郎; 平岡美紀; 村田美幸; 北市伸義; FOXTON Richard; 石田晋, 日本眼科学会雑誌, 126, 臨増, 210, 210, 2022年
(公財)日本眼科学会, 日本語 - ベーチェット病ぶどう膜炎に対するインフリキシマブ治療の5年以上の検討:多施設研究
竹内大; 臼井嘉彦; 南場研一; 慶野博; 竹内正樹; 高瀬博; 鴨居功樹; 長谷敬太郎; 伊東崇子; 中井慶; 丸山和一; 小林恵理; 堀純子; 真下永; 佐藤智人; 大黒伸行; 岡田アナベルあやめ; 園田康平; 後藤浩; 水木信久, 日本眼科学会雑誌, 126, 臨増, 238, 238, 2022年
(公財)日本眼科学会, 日本語 - Plasminogen activator inhibitor-1阻害薬による実験的自己免疫性ぶどう膜炎の軽症化
鈴木佳代; 岩田大樹; 南場研一; 長谷敬太郎; 平岡美紀; 村田美幸; 北市伸義; 大野重昭; 石田晋, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 58th-55th-64th-10th, 2022年 - 著明な脈絡膜萎縮に至ったフォークト-小柳-原田病における脈絡膜画像所見
荻野陽; 南場研一; 岩田大樹; 水内一臣; 長谷敬太郎; 鈴木佳代; 石田晋, 日本眼科学会雑誌, 125, 臨増, 210, 210, 2021年
(公財)日本眼科学会, 日本語 - 抗Angopoietin2/Vascular endothelial growth factor二重特異性抗体を用いたぶどう膜炎の軽症化
鈴木佳代; 岩田大樹; 南場研一; 荻野陽; 長谷敬太郎; 水内一臣; 平岡美紀; 北市伸義; FOXTON Richard; 石田晋, 日本眼薬理学会プログラム・講演抄録集, 41st, 45, 45, 2021年
日本眼薬理学会, 日本語 - 眼底自発蛍光が再発検出・治療選択に有用であった急性後部多発性斑状色素上皮症の1例
横井康一; 南場研一; 岩田大樹; 水内一臣; 長谷敬太郎; 鈴木佳代; 廣岡季里子; 関根伸子; 石田晋, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 57th-54th-63rd-9th, 2021年 - 注目のイチオシ論文 : やさしく解説(第16回)レチノール結合蛋白3は糖尿病網膜症に拮抗して糖尿病患者の網膜内では上昇している—Yokomizo H et al : Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med 11 : eaau6627, 2019
長谷 敬太郎; 神田 敦宏, Retina medicine : journal of retina medicine : 網膜・硝子体領域を中心とした医学情報誌 / Retina Medicine誌編集委員会 編, 9, 1, 62, 64, 2020年
東京 : 先端医学社, 日本語 - 網膜色素上皮細胞における胎盤成長因子による血管内皮増殖因子受容体-2の安定化機序
村田美幸; 野田航介; 長谷敬太郎; WU Di; 神田敦宏; 石田晋, 糖尿病合併症, 33, Supplement 1, 271, 271, 2019年
(一社)日本糖尿病合併症学会, 日本語 - 人工多能性幹細胞由来マクロファージ様免疫抑制細胞を用いたぶどう膜炎モデルの軽症化
長谷敬太郎; 南場研一; 北市伸義; 岩田大樹; 辻飛雄馬; 和田はるか; 清野研一郎; 石田晋, 日本眼科学会雑誌, 123, 臨増, 226, 226, 2019年
(公財)日本眼科学会, 日本語 - 眼サルコイドーシスの診断における血液検査・画像検査の有用性
鈴木佳代; 南場研一; 水内一臣; 岩田大樹; 福原崇子; 長谷敬太郎; 濱田怜; 大野重昭; 北市伸義; 石田晋, 日本眼科学会雑誌, 122, 臨増, 191, 191, 2018年
(公財)日本眼科学会, 日本語 - 眼サルコイドーシスの診断における各種検査の有用性検証
鈴木佳代; 南場研一; 水内一臣; 岩田大樹; 福原崇子; 長谷敬太郎; 濱田怜; 大野重昭; 北市伸義; 石田晋, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 38, サプリメント号, 64, 64, 2018年
日本サルコイドーシス, 日本語 - 増殖糖尿病網膜症患者における血漿ガレクチン-1と炎症関連分子との相関解析
長谷敬太郎; 神田敦宏; 野田航介; 石田晋, 日本眼科学会雑誌, 122, 臨増, 237, 237, 2018年
(公財)日本眼科学会, 日本語 - 網膜色素上皮細胞における胎盤成長因子のアポトーシス抑制効果
村田美幸; 野田航介; 長谷敬太郎; 神田敦宏; 石田晋, 日本網膜硝子体学会総会プログラム・講演抄録集, 57th, 11, 850, 850, 2018年
眼科臨床紀要会, 日本語 - 線維柱帯組織の採取と病理学的研究—特集 臨床検体で科学する!
新明 康弘; 長谷 敬太郎; 加瀬 諭, Retina medicine : journal of retina medicine : 網膜・硝子体領域を中心とした医学情報誌 / Retina Medicine誌編集委員会 編, 7, 1, 55, 58, 2018年
東京 : 先端医学社, 日本語 - 肺粟粒結核に伴う結核性眼内炎の1例
長谷敬太郎; 南場研一; 竹本裕子; 齋藤航; 中村佳代子; 今野哲; 網島優; 大野重昭; 石田晋, 日本眼感染症学会・日本眼炎症学会・日本コンタクトレンズ学会総会・日本涙道・涙液学会プログラム・講演抄録集, 49th-46th-55th-1st, 2012年
- 全科臨床実習, 2024年, 学士課程, 医学部
- 基本医学総論, 2024年, 修士課程, 医学院
- 診療参加型選択科臨床実習, 2024年, 学士課程, 医学部
- 基本医学研究, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床生理学Ⅲ, 2024年, 学士課程, 医学部
■ 共同研究・競争的資金等の研究課題
- ぶどう膜炎におけるリン脂質酸化物の動態と網膜障害軽症化の試み
科学研究費助成事業
2023年02月26日 - 2025年03月31日
長谷 敬太郎
ぶどう膜炎モデルマウスの誘導にはこれまでヒト視細胞間レチノイドタンパク合成ペプチド(hIRBPp)1-20が最もよく用いられてきた。しかし、炎症が非常に弱く、炎症が起きないこともあることが、問題となっている。近年、ぶどう膜炎モデルマウスのためのhIRBPp651-670という新たなペプチドが開発され、強い炎症が得られ、ぶどう膜炎発症の割合も良いという報告もある(Mattapallil MJ et al. Invest Ophthalmol Vis Sci. 2015)。そこで、より良いぶどう膜炎モデルマウスを確立するために、従来のhIRBPp1-20と新たなhIRBPp651-670という2種類のペプチドによって誘導したぶどう膜炎モデルマウスの炎症の強さを比較した。
その結果、臨床的炎症スコア(平均値)は、注射後14日目では、hIRBPp1-20群では0.3、hIRBPp651-670群では3.4であった。注射後17日目では、hIRBPp1-20群では0.5、hIRBPp651-670群では3.9であった。注射後21日目では、hIRBPp1-20群では1.3、hIRBPp651-670群では3.9であった。Mann-Whitney U検定では、注射後14日目(P < 0.0001)、17日目(P < 0.0001)、21日目(P < 0.0001)で有意差が認められた。注射後21日目の眼球組織学的炎症スコアでも、Mann-Whitney U検定でP < 0.0001であり、有意にhIRBPp651-670群ではhIRBPp1-20群に比べて組織学的にも炎症が強かった。以上の結果から、hIRBPp1-20よりhIRBPp651-670を用いて誘導したぶどう膜炎モデルマウスの方が安定して強い炎症が得られ、実験に用いるのには適していることがわかった。
日本学術振興会, 研究活動スタート支援, 北海道大学, 20K22990
